 DURHAM, N.C.--BUSINESS WIRE--Aerie Pharmaceuticals, Inc. NASDAQ: AERI, an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that Roclanda 50 microgramsml 200 microgramsml Eye Drops, Solution latanoprost netarsudil Roclanda has received marketing authorisation from the Medicines and Healthca 